Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-arm, Open-label, Long-term Safety Rollover Trial of Oral Brigimadlin in Patients With Solid Tumours

NCT06619509 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06619509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06619509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-arm, Open-label, Long-term Safety Rollover Trial of Oral Brigimadlin in Patients With Solid Tumours
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 30, 2024
Completion date
December 30, 2030
Enrollment
90 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours